Jeffrey A. Bluestone joins Gilead Sciences’ Board of Directors
FOSTER CITY: Gilead Sciences Inc. announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors. Dr. Bluestone is the...
Gilead Sciences to acquire Immunomedics in a $21 billion deal
SACRAMENTO: Gilead Sciences Inc. and Immunomedics have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88/share in cash. The transaction,...
Dr. Reddy’s Laboratories enters into a licensing agreement with Gilead Sciences for Remdesivir
PRINCETON: Dr. Reddy’s Laboratories has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy’s the right to register,...